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Interferon lambdas (IFNλs) are recently discovered cytokines acting not only at the 
first line of defense against viral infections but also at the mucosal barriers. In fact, a 
peculiar feature of the IFNλ system is the restricted expression of the functional IFNλR, 
which is known to be limited to epithelial cells and discrete leukocyte subsets, including 
the plasmacytoid dendritic cells (pDCs). In the latter case, current data, discussed in 
this minireview, indicate that IFNλs positively regulate various pDC functions, including 
pDC expression of interferon-dependent gene (ISG) mRNAs, production of cytokines, 
survival, and phenotype. Although the knowledge of the effects on pDCs by IFNλs is still 
incomplete, we speculate that the peculiar pDC responsiveness to IFNλs provide unique 
advantages for these innate immune cells, not only for viral infections but also during 
autoimmune disorders and/or tumors, in which pDC involvement and activation variably 
contribute to their pathogenesis.
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inTRODUCTiOn
Human dendritic cells (DCs) in the blood typically include the myeloid DCs (mDCs), enlisting 
the BDCA1+/CD1c+ and BDCA3+/CD141+ DCs, as well as the plasmacytoid DCs (pDCs) (1). All 
peripheral DCs originate from a common DC progenitor (2) and act as antigen-presenting cells 
(APCs) to initiate adaptive immune responses (3). Among DCs, pDCs are distinguishable given their 
peculiar phenotype, tissue localization, and specialized functions (4). pDCs constitute 0.2–0.6% 
of the peripheral blood mononuclear cells (PBMCs) in healthy individuals (5) and are specialized 
in the production of type I interferon (IFN) (6–8). Human pDCs specifically express the C-type 
lectin BDCA2/CD303 molecule, the alpha chain of the interleukin-3 receptor (IL-3Rα/CD123), 
and neuropilin-1/BDCA4 (9), but not CD11c, which is instead expressed by mDCs (1, 3). Under 
steady state conditions, pDCs localize in the T cell areas of the lymph nodes (LNs), while they are 
undetectable in almost all peripheral tissues (5, 10). Migration of pDCs into LNs and inflamed tissues 
involves discrete adhesion molecules (CD62L, PSGL-1, β1- and β2-integrin), as well as activated 
chemokine receptors, including CXCR3, CXCR4, CCR2, CCR5, and CCR7 (11, 12). Once recruited 
into tissues, pDCs orchestrate immune responses, as well as interact with, activate, or are activated 
by T, B, NK cells, and other leukocytes (4, 13, 14).
Plasmacytoid dendritic cells are specialized in recognizing viral and/or self/non-self nucleic acids, 
for instance through TLR7 and TLR9, to ultimately produce IFNα following an intracellular signal-
ing cascade activating interferon regulatory factor 7 (IRF7) (15). IFNα, in turn, not only induces the 
transcription of interferon-dependent genes (ISGs) to limit the spread of viral pathogens (16) but 
also amplifies immune responses by modulating selected functions of NK, myeloid, B and T cells 
(17,  18). TLR7/9 engagement also leads pDCs to differentiate into mature cells, thus acquiring 
a more DC morphology and APC capacity (5, 19, 20). Similar effects on pDCs are observed in 
response to IL-3, a cytokine also known to maintain pDCs alive (10). Accordingly, TLR and/or 
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IL-3-stimulated pDCs upregulate the expression of MHC-II and 
costimulatory molecules (including CD80, CD86, and CD40), 
as well as produce both proinflammatory cytokines (TNFα and 
IL-6) and chemokines (CCL4, CCL5, CXCL9, and CXCL10) (7, 
11, 13, 21). Notably, endogenous TNFα concurs to pDC matura-
tion (22), while autocrine/paracrine IFNα promotes the survival 
of pDCs via induction of antiapoptotic genes (23). Activated/
mature pDCs, in turn, become able to promote the polarization 
of T helper lymphocytes into Th1, Th2, Th17, or also Treg cells, 
depending on the context (7, 8, 10, 24).
Plasmacytoid dendritic cells also produce type III IFNs/IFNλs 
(25), for instance in response to HSV (26–28), Sendai virus (27), 
Flu (27), Imiquimod/R837 (synthetic TLR7 ligands) (26–29), 
CpG oligodeoxyribonucleotides (26–28, 30–32), or upon cocol-
ture with hepatitis C virus (HCV)-infected Huh7.5 (30, 31). The 
IFNλ family includes four members, three of them identified in 
2003 (e.g., IFNλ1/IL-29, IFNλ2/IL-28A, and IFNλ3/IL-28B), the 
fourth one (IFNλ4), which shares only ~30% identity with other 
IFNλs, but signals through the same receptor complex, discov-
ered more recently (2013) (33). IFNλs not only display potent 
antiviral activities (34–36) but also exert other effects involved in 
autoimmunity and tumor progression (37, 38). Moreover, it has 
become increasingly clear that IFNλs evolved to serve as a first 
line of defense at the mucosal barrier, particularly at the level of 
the respiratory and gastrointestinal tracts, which are the initial 
target of most invasive pathogens (36). In fact, a peculiarity of the 
IFNλ system is the restricted distribution of the IFNλR (39–41), 
which consists of a specific IFNλR1 chain (also known as IL-28R), 
and the ubiquitously expressed IL10R2 chain (40, 41). Epithelial 
cells of the intestine, lungs, skin, and liver constitutively express 
the IFNλR1 chain and thus represent the primary targets of IFNλs 
(42). In such regard, there has been a great interest in specifi-
cally characterizing the antiviral role of IFNλs during HCV and 
hepatitis B virus infections (43–47). In the former case, in fact, 
although not yet explained in the context of HCV pathogenesis, 
several genome-wide association studies have demonstrated a link 
between single-nucleotide polymorphisms near the IFNλ3 and 
IFNλ4 genomic loci and either the spontaneous clearance or the 
sustained response to IFNλ-treatment in HCV-infected patients 
(48–50). Moreover, IFNλ1 has been used for clinical trials in HCV 
patients (51) confirming an antiviral efficacy equivalent to IFNλ, 
but with less toxicity (51). Fibroblasts, splenocytes, bone marrow 
(BM)-derived macrophages, and endothelial cells do not express 
IFNλR1 and thus do not respond to IFNλs (42, 52, 53). Among 
human leukocytes, only pDCs and, less prominently, B cells, have 
been shown to constitutively express a complete IFNλR (26, 27). 
Consistently, IFNλs have been shown to trigger phosphorylation 
of STAT1 (27, 54, 55), STAT2 (54), STAT3, and STAT5 (55), in 
either freshly isolated pDCs (54) or pDCs gated among total 
PBMCs (27, 55), as well as various functional responses herein 
summarized.
PRODUCTiOn OF CYTOKines  
BY pDCs inCUBATeD wiTH iFnλs
Interferon lambdas have been described to stimulate the produc-
tion of cytokines and chemokines in pDCs. We reported that 
human pDCs incubated for up to 42 h with 30 IU/ml IFNλ1 or 
IFNλ3 produce variable, but significant, levels of CXCL10, usually 
(but not always) followed by IFNα (54). Consistently, experiments 
using anti-IFNαR antibodies only partially blocked CXCL10 
derived from pDCs incubated with IFNλ3 for 42 h (54). Notably, 
healthy donors could be categorized into two groups based on 
the levels of IFNα produced by their IFNλ3-treated pDCs [e.g., 
very modest ≤150 pg/ml/42 h: elevated ≥500 pg/ml/42 h] (54). 
By similar criteria, referred instead to CXCL10, healthy donors 
could be independently divided into three groups: one having 
pDCs producing modest quantities of CXCL10 (ranging from 
22 ± 11 pg/ml/18 h to 163 ± 24 pg/ml/42 h); another one, hav-
ing pDCs producing elevated CXCL10 levels already after 18 h 
(865 ± 297 pg/ml) without further increasing thereafter; and a 
third one, having pDCs producing maximal CXCL10 levels after 
42 h of IFNλ3-treatment (1,320 ± 264 pg/ml) (54). It should be 
pointed out that such an extremely variable production of both 
IFNα and CXCL10 were shown not to depend on differences in 
the viability of pDCs among the donor groups. Moreover, the 
patterns of CXCL10 production by pDCs somewhat recalled 
previous data (56), likely attributable to pDCs, in which PBMCs 
from healthy donors were described to function either as “early” 
or as “late” responders to 3,500 IU/ml IFNλ1, depending, respec-
tively, on the more rapid or more delayed kinetics of CXCL9, 
CXCL10, and CXCL11 transcript induction. Whatever the case 
is, the molecular bases underlying the variable capacity of pDCs 
to produce IFNα and CXCL10 by the different donor typologies, 
as well as their potential biologic implications, require further 
investigations.
In addition to CXCL10 and IFNα, we also detected low but bio-
logically active amounts of TNFα in supernatants harvested from 
purified pDCs incubated with IFNλ3 (54). In fact, experiments in 
which supernatants from IFNλ3-treated pDCs were transferred 
to CD14+-monocytes in the presence or absence of reagents 
inhibiting TNFα, namely etanercept (ETA) and adalimumab, 
revealed that they induced CCL4 and IκBα mRNA expression in 
a TNFα-dependent manner (54). It should be pointed out that, 
in contrast with our results, 3,500 IU/ml IFNλ1-treated PBMCs 
were previously found able to produce CXCL8, IL-6, and IL-10, 
but not TNFα or IL-1α (57), possibly because of the short stimula-
tion period. Similarly, Flt3-generated BM-derived murine pDCs 
incubated with IFNλ2 were found unable to produce CXCL10 
and IL-6 (58). However, whether Flt3-generated BM-derived 
murine pDCs express the complete IFNλR, or whether their 
blood counterpart behaved as human pDCs, was not reported.
Because flow cytometry experiments uncovered that both 
IFNλ3 and IL-3 increase the levels of surface CD123 and IFNλR1 
in human pDCs (54, 59), in a subsequent study, we investigated 
whether IFNλ3 and IL-3 together could promote stronger pDC 
responses. This was found to be the case, as we could show that 
30 IU/ml IFNλ3 and 20 ng/ml IL-3 induce in pDCs a synergistic 
production of both IFNα and TNFα (59). Moreover, endogenously 
produced TNFα was found to almost completely control the syn-
ergistic production of IFNα in IFNλ3 plus IL-3-treated pDCs (59). 
Under the same experimental conditions, or in pDCs incubated 
with IFNλ3 only, endogenously produced IFNα did not drive ISG 
mRNA expression, unlike its effect in IL-3-treated pDCs. On the 
TABLe 1 | Biological effects of interferon lambdas in human plasmacytoid dendritic cells (pDCs).
iFnλ type Dose investigated 
response in 
pDCs
Outcome Modality of detection Reference
IFNλ3 30–100 IU/ml Modulation of 
IFNλR expression 
Increase of mRNA and surface IFNλR1 Real-time qPCR and flow cytometry [(59) and our 
unpublished 
observations]
IFNλ1, IFNλ2, IFNλ3 35–350 IU/ml Activation 
of signaling 
pathways
Induction of STAT-1, -3, -4, and -5 
phosphorylationa
Flow cytometry (27, 55)
IFNλ3 30 IU/ml Induction of STAT-1 and -2 phosphorylation Immunoblotting (54)
IFNλ1 35–350 IU/ml Modulation 
of maturation 
markers
Upregulation of CD80, ICOS-L, CD62L, 
CD83, MHC-Ia
Flow cytometry (26, 27)
IFNλ1, IFNλ3 30–100 IU/ml Upregulation of HLA-DR, CD123, CD83, 
CD86, CD303, CD62L
Flow cytometry (54, 59)
IFNλ1 35–350 IU/ml Survival Counteraction of the proapoptotic effect 
exerted by Dexamethasonea
Annexin V/propidium iodide staining and 
intracellular detection of active caspase-3
(27)
IFNλ1, IFNλ3 30–100 IU/ml Prosurvival effect Vybrant DyeCycle Violet stain (54, 59)
IFNλ1 350 IU/ml Influence on T cell 
functions
Inhibition of IL-10, IL-13, and IFNγ production 
by PMA and ionomycin-activated allogenic 
T cells
ELISA (26)
IFNλ1, IFNλ3 30–350 IU/ml ISG mRNA 
expression
Induction of MX1, protein kinase R, IFIT1, 
ISG15, and CXCL10 transcripts
Real-time qPCR (54, 55, 59, 60)
IFNλ3 30 IU/ml Induction of IFIT2, TLR7, TRAIL, TNFα, IFNα 
transcripts
Real-time qPCR [(54, 59) and 
our unpublished 
observations]
IFNλ2 100 ng/ml Induction of oligoadenylate synthetase 1 
and interferon regulatory factor 7 transcripts 
(mouse pDCs)
Real-time qPCR (52)
IFNλ1 25 ng/ml Cytokine 
production
Enhancement of IFNα production in response 
to hepatitis C virus-infected hepatoma cells 
or CpG-A
ELISA (30)
IFNλ1 35 IU/ml Priming effect and enhancement of IFNα and 
IFNλ1/3-positive pDCs in response to HSVa
Flow cytometry (27)
IFNλ1, IFNλ3 30–100 IU/ml Induction of time-dependent production of 
CXCL10, IFNα and TNFα
ELISA (54)
IFNλ3 30 IU/ml Enhancement of IL-3-induced IFNα and TNFα 
production
ELISA (59)
aIn these papers, pDCs have been identified as BDCA2+/CD123+ or Lin−/CD123+ cells, by flow cytometry, within peripheral blood mononuclear cells previously labeled with a 
combination of specific antibodies.
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other hand, endogenous TNFα was found to drive ISG mRNA 
expression in both IFNλ3- and IL-3-stimulated pDCs (59).
eXPReSSiOn of iSG mRnAs AnD 
PHOSPHORYLATiOn of STATs  
in iFnλ-TReATeD pDCs
Plasmacytoid dendritic cells have been shown to de novo 
express a variety of ISG mRNAs in response to IFNλs, which 
further support the protective role of the IFNλ/pDC system in 
viral infections. For example, 2’-5’-oligoadenylate synthetase 
1 (OAS1) and IRF7 mRNAs were found as induced in murine 
pDCs incubated with 100 ng/ml IFNλ2 (52). In humans, we and 
others have reported that both IFNλ1 and IFNλ3 induce the 
mRNA expression of MX dynamin like GTPase 1 (MX1) (59, 60), 
protein kinase R (PKR), interferon induced protein with tetratri-
copeptide repeats 1 (IFIT1), ISG ubiquitin-like modifier (ISG15), 
and C-X-C motif chemokine ligand 10 (CXCL10) (54, 55, 59). 
Our unpublished observations prove that also CXCL9, TLR7, 
IFIT2, and TNF-related apoptosis inducing ligand (TRAIL) are 
induced by IFNλ3 in human pDCs. All these mRNAs were shown 
to reach maximal levels after 18 h of incubation of pDCs treated 
with 30 IU/ml IFNλ1 or IFNλ3 (54). Experiments conducted in 
pDCs preincubated in the presence of anti-IFNαR antibodies, 
and then cultured with IFNλ3 plus IL-3, which, at the 18 h-time 
point, express and release much higher levels of, respectively, 
ISG mRNAs and IFNα, than pDCs incubated with IFNλ3 alone 
(59), revealed that endogenous IFNα is minimally involved in 
autocrinally activating ISG mRNA expression (59). Consistently, 
and even though IFNα is typically considered more potent 
than IFNλ in inducing ISG gene expression, we observed that 
equivalent concentrations of IFNλ3 and IFNα (e.g., 30  IU/ml) 
induce, in human pDCs, comparable levels of STAT1 and STAT2 
phosphorylation and ISG15, IFIT1, and MX1 transcripts (our 
unpublished observations). However, we also noticed that kinet-
ics of both STAT phosphorylation and ISG mRNA induction were 
more accelerated in response to IFNα than IFNλ3, consistent 
4Finotti et al. Effects of IFNλs on Plasmacytoid DCs
Frontiers in Immunology | www.frontiersin.org August 2017 | Volume 8 | Article 1015
with studies in other cells (61–63). It should be also pointed 
out that, in a previous study, the levels of MX1 mRNA induced 
by IFNα in purified pDCs were found to be higher than those 
induced by IFNλ3 (60), but IFNα was used at concentrations 
approximately 10-fold higher than IFNλ3 (1,000 vs 100 IU/ml, 
respectively). Under similar experimental conditions, only IFNα, 
but not IFNλs, was shown to activate STAT6 phosphorylation in 
purified pDCs (55), independently from the concentrations used.
Recent evidence suggests that, under specific experimental 
settings, IFNα/β and IFNλ control gene expression, as well 
FiGURe 1 | Illustration depicting the potential antitumorigenic role that IFNλs might have within a tumor microenvironment. Accordingly, IFNλs may directly act on 
tumor cells, may activate local plasmacytoid dendritic cells (pDCs), or may favor the recruitment and activation of immune cells via pDC-derived IFNα, TNFα and 
CXCL10.
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as contribute to the antiviral state, by using different and 
non-redundant mechanisms. For instance, unlike IFNβ (64), 
IFNλ1 and IFNλ2 were shown to activate an alternative signal-
ing pathway involving Jak2 in UMUC-3 and Huh7.5 cell lines 
(64, 65). Similarly, the antiviral activity induced in T84 cell lines 
by IFNλs, but not IFNα, was found to be strongly dependent on 
the mitogen-activated protein kinases (MAPKs) activation (66). 
However, whether IFNλ activates Jak2 and/or MAPK in pDCs is 
currently unknown.
iFnλs PROMOTe THe SURvivAL OF pDCs
Plasmacytoid dendritic cells are known to spontaneously undergo 
apoptosis when cultured in vitro (10, 22). In this context, one of the 
remarkable effects that IFNλs exert in pDCs freshly purified from 
the blood is to prolong their survival for up to 42 h (54), similarly 
to IL-3 (54). While equivalent concentrations of IFNλ1 or IFNλ3 
(30 and 100  IU) were found to exert comparable prosurvival 
activities in pDCs, no further enhancement was observed when 
IFNλ3 was used in combination with IL-3, indicating that each 
cytokine produces already the maximal prosurvival effect by itself 
(59). In additional experiments, we found that both endogenous 
TNFα and IFNα partially sustain the survival of pDCs cultured 
in the presence of IFNλ3. Similarly, anti-IFNαR antibodies were 
found to decrease survival of pDCs incubated with IL-3 alone 
(our unpublished observations) or CpG-C plus glucocorticoids 
(23), while TNFα blockers had no or only a slight effect under 
the same conditions (22, 23). However, no modulation of sur-
vival was found by inhibiting both TNFα and IFNα in pDCs 
cultured with IFNλ3 plus IL-3. Conceptually, our data not only 
confirm, but further support, previous observations showing that 
35–350  IU/ml IFNλ1 counteracts the proapoptotic effects that 
dexamethasone (DEX) exerts in pDCs present within PBMCs 
(27). The molecular mechanisms whereby IFNλs promote pDC 
viability are unknown and should be characterized.
iFnλs MODULATe THe eXPReSSiOn OF 
vARiOUS SURFACe MARKeRS in pDCs
In addition to inducing cytokine production and ISG mRNA 
expression, or promoting survival, IFNλs have been shown 
to trigger the maturation of pDCs, according to phenotypic 
changes. For instance, incubation of PBMCs with 35–350 IU/ml 
IFNλ1 for 7 or 20  h has been shown to weakly increase the 
surface expression of CD80, ICOS-L, CD62L, CD83, CCR7, 
and MHC-I, but not of CD86, in CD123+/CD303+-gated-pDCs 
(26, 27). By using freshly isolated pDCs, we could confirm that 
30–100  IU/ml IFNλ3 potently and persistently (e.g., for up to 
42 h) modulates the expression of CD86, HLA-DR, CD123, and 
CD303, in addition to CD62L and CD83. However, in contrast 
with the data by Megjugorac et al. (26), we found an upregulation 
of CD86 upon treatment of pDCs with IFNλ3 for 42 h. Although 
IFNλ3-mediated effects substantially resembled those induced 
by IL-3 (54, 59), IFNλ3 appeared significantly less potent in 
upregulating HLA-DR or CD86 expression, or in downmodulat-
ing CD303 and CD62L, consistent with a weaker maturational 
effect on pDCs. Functionally, only one study (26) has specifically 
analyzed whether 350 IU/ml IFNλ1-treated pDCs could activate 
CD4+ T cells. Accordingly, it has been reported that cocultures 
of IFNλ1-treated pDCs with allogenic T cells, activated by PMA/
ionomycin, produce reduced levels of IL-10, IL-13, and IFNγ 
than in the absence of IFNλ1 (26). Whether IFNλ-treated pDCs 
promote Th1, Th2 or Treg polarization has not been specifically 
investigated yet.
COnCLUSiOn
As synthetically outlined in this minireview, current data 
suggest that IFNλ is able to regulate pDC functions at various 
levels (as summarized in Table 1), including the production of 
IFNα, CXCL10, and TNFα. Because IFNα has been shown to 
increase the production of IFNλ by CD141+ DCs in response 
to HCV-infected hepatoma cells or poly-I:C (30), data testify 
for potential cross talk between pDCs and CD141+ DCs via the 
two IFN systems. A strict cross talk between pDCs and B cells 
has been also described, as B cells are known to enhance IFNα, 
and possibly IFNλs, production by pDCs, via cell–cell contact-
dependent mechanisms or soluble factors (14). Conversely, TNFα 
and CXCL10 secreted by IFNλ-activated pDCs might contribute 
to, respectively, amplify local inflammatory responses and recruit 
activated T lymphocytes. On the same line, modulation of pDC 
membrane markers by IFNλ might influence T cell polarization, 
either promoting or impairing T  cell responses, depending on 
the context. Thus, in vitro experiments suggest that IFNλs could 
orchestrate complex immune cell interactions by amplifying 
pDC responses, both directly and indirectly. Since in vitro pDCs 
increase the expression of IFNλR1 in response to IL-3 (59), IFNλ3 
(59), or R837 (our unpublished observations), it is likely that this 
phenomenon also happens at the site of infection in response to 
viral particles or other stimuli. However, whether IFNλR1 modu-
lation positively or negatively affects pDC response to IFNλ, and, 
in turn, pDC cross talk with other immune cell subpopulations, is 
not known. Similarly, even though there are three splice variants 
of the human IFNλR1 gene, encoding either the full length func-
tional IFNλR1, a soluble IFNλR1, or an IFNλR1 variant lacking 
a membrane-proximal region of the intracellular domain and 
expected to be signal-incapable (67), no information is present 
on how they are regulated in pDCs.
As mentioned, given the peculiar expression of IFNλR1 in 
hepatocytes, clinical trials of IFNλ1 therapy for HCV infection 
have confirmed that this cytokine has antiviral effects equivalent 
to IFNα without the same level of associated toxicity (51). Studies 
of IFNλ treatment of influenza A virus-infected mice have shown 
similar results (58). In this context, it would be interesting to 
determine if, and how, circulating and/or tissue resident pDCs 
are affected by the IFNλ-treatment. Such knowledge might 
eventually help clarifying the in  vivo biologic implication(s) of 
the variable capacity of pDCs to produce IFNα and CXCL10 by 
the various donor typologies that we described (54). Regardless, 
treatment with IFNλs might be also useful in patients with 
autoimmune disorders. A tissue infiltration by pDCs, as well as a 
type I IFN signature, has been in fact described in SLE, Sjogren’s 
syndrome, systemic sclerosis, and psoriasis patients (4). In these 
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